Nanologica AB NICA
This picture changes. Follow Nanologica AB free — email when the signal or risk changes + a Sunday weekly brief.
Follow Nanologica AB freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 26 Jan 2026
Latest news check: 2 Aug 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Wait/hold until the company delivers 1–2 quarters of stable underlying operating performance and cash flow from the combined CDMO platform. Watch Q2 (27 Aug) for organic trends, integration costs, and order intake.
The acute financing risk has decreased after completed share issues and debt set-offs together with a substantially stronger cash position, yet the reported Q1 profit is largely a one-off effect from the acquisition, so the investment case now centres on integration, CDMO margins and sustainable revenue growth.
Market sentiment
6/10
↑
Trend: Improving
Sentiment has improved to weak/near-neutral after the Q1 release and a strengthened balance sheet, but investors remain cautious as the profit uplift is largely acquisition accounting and integration/underlying cash generation still needs to be proven.
Price context
The share trades near historical lows at 0.444 SEK after a 16.9 % decline over three months with low liquidity, signalling weak momentum pending operational progress.
Risk assessment
8/10
Dilution:
High
Jurisdiction:
Low
Execution:
High
Cash flow:
3 mo
Recent changes
- Revenue was 21.5 MSEK (10.8) and operating profit 66.5 MSEK, largely driven by a one-off item (78.9 MSEK) related to the Syntagon acquisition. Cash was 39.3 MSEK at March 31 plus roughly 34 MSEK received in April before…
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company free
Type:
Biotech
Next report
27 Aug 2026
Q2
Catalysts
27 Aug 2026
Q2 2026: first quarter with clearer integration imprint
High
Sep 2026
Exercise of warrants TO 2023/2026
Medium
Horizon:
Bull case
Order intake from strategic markets such as the US and China could provide positive momentum if stabilised production reduces the risk of delivery delays.
Bear case
Low cash liquidity raises concern for an imminent new share issue and continued negative cash flow puts pressure on valuation if no breakthrough orders are announced.
Signal rationale (informational)
The acute financing risk has decreased after completed share issues and debt set-offs together with a substantially stronger cash position, yet the reported Q1 profit is largely a one-off effect from the acquisition, so the investment case now centres on integration, CDMO margins and sustainable revenue growth.
Recent news
- No material press releases regarding deals, financing or operational breakthroughs have been communicated after 2026-07-02. The next scheduled event is the Q2 interim report on 27 August 2026.
Price & valuation
Last close
SEK 0.46
Market Cap
SEK 150M
1 week
-0.4 %
3 months
+0.2 %
Exchange
Stockholm
Type
Biotech
This picture changes. Follow Nanologica AB free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.